Inventor · disambiguated record
Peter Van Vlasselaer
Also filed as: VAN VLASSELAER PETER
27 granted patents·13 pending applications·1,318 citations·filing 1994–2025
97Inventor score
Files withBIOVERATIV USA INC10TRUE NORTH THERAPEUTICS INC8ACTIVATED CELL THERAPY INC5GILEAD BIOLOGICS INC5SMITH VICTORIA4
Top patents by PatentIndex Score
40 records- 0198US5840502AMethods for enriching specific cell-types by density gradient centrifugationACTIVATED CELL THERAPY INC·Filed 1994·Granted Nov 24, 1998·384 cites·13 claims
- 0296US9206259B2Methods of inhibiting complement C4 activation with anti-complement C1S antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2015·Granted Dec 8, 2015·15 cites·13 claims
- 0396US8945562B2Anti-complement C1s antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2013·Granted Feb 3, 2015·24 cites·47 claims
- 0496US8877197B2Anti-complement C1sTRUE NORTH THERAPEUTICS INC·Filed 2014·Granted Nov 4, 2014·22 cites·25 claims
- 0594US9562092B2Methods of inhibiting complement C4 activation with anti-complement C1s antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2015·Granted Feb 7, 2017·10 cites·13 claims
- 0694US9512233B2Anti-complement C1s antibodies and methods of inhibiting complement C1s activityTRUE NORTH THERAPEUTICS INC·Filed 2015·Granted Dec 6, 2016·12 cites·41 claims
- 0794US9074004B2Methods of inhibiting activation of complement component C4 with anti-C1s antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2014·Granted Jul 7, 2015·15 cites·13 claims
- 0894US9074003B2Methods of inhibiting activation of complement component C4 with anti-C1s antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2014·Granted Jul 7, 2015·15 cites·30 claims
- 0994US8461303B2LOX and LOXL2 inhibitors and uses thereofSMITH VICTORIA·Filed 2008·Granted Jun 11, 2013·30 cites·30 claims
- 1093US12215169B2Anti-complement C1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2021·Granted Feb 4, 2025·1 cites·21 claims
- 1193US10450382B2Anti-complement C1s antibodiesBIOVERATIV USA INC·Filed 2016·Granted Oct 22, 2019·8 cites·9 claims
- 1293US8658167B2Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasisGILEAD BIOLOGICS INC·Filed 2012·Granted Feb 25, 2014·19 cites·30 claims
- 1393US5577513ACentrifugation syringe, system and methodACTIVATED CELL THERAPY INC·Filed 1994·Granted Nov 26, 1996·214 cites·35 claims
- 1492US9176139B2LOX and LOXL2 inhibitors and uses thereofGILEAD BIOLOGICS INC·Filed 2013·Granted Nov 3, 2015·16 cites·60 claims
- 1592US5648223AMethods for enriching breast tumor cellsACTIVATED CELL THERAPY INC·Filed 1994·Granted Jul 15, 1997·103 cites·18 claims
- 1692US2025263503A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2024·Application pending·0 cites
- 1791US9562106B2Anti-complement C1s antibodies and methods of inhibiting complement C1s activityTRUE NORTH THERAPEUTICS INC·Filed 2015·Granted Feb 7, 2017·8 cites·31 claims
- 1891US5646004AMethods for enriching fetal cells from maternal body fluidsACTIVATED CELL THERAPY INC·Filed 1994·Granted Jul 8, 1997·162 cites·19 claims
- 1990US10457745B2Anti-complement C1s antibodiesBIOVERATIV USA INC·Filed 2016·Granted Oct 29, 2019·6 cites·10 claims
- 2086US8679485B2Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasisSMITH VICTORIA·Filed 2008·Granted Mar 25, 2014·6 cites·44 claims
- 2182US12240917B2Anti-complement C1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2021·Granted Mar 4, 2025·0 cites·13 claims
- 2282US2025188192A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2025·Application pending·0 cites
- 2375US5474687AMethods for enriching CD34+ human hematopoietic progenitor cellsACTIVATED CELL THERAPY INC·Filed 1994·Granted Dec 12, 1995·157 cites·32 claims
- 2472US9823255B2Method for assessing protein identity and stabilityARMO BIOSCIENCES INC·Filed 2014·Granted Nov 21, 2017·1 cites·5 claims
- 2572US2020079875A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2019·Application pending·0 cites
- 2670US2025145696A1Methods for treating complement-mediated diseases and disordersBIOVERATIV USA INC·Filed 2024·Application pending·0 cites
- 2768US2020079876A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2019·Application pending·0 cites
- 2867US6015843AProcess for making silanized colloidal silicaDENDREON CORP·Filed 1998·Granted Jan 18, 2000·22 cites·10 claims
- 2964US10494443B2LOX and LOXL2 inhibitors and uses thereofGILEAD BIOLOGICS INC·Filed 2016·Granted Dec 3, 2019·0 cites·22 claims
- 3064US2014128284A1Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasisGILEAD BIOLOGICS INC·Filed 2013·Application pending·0 cites
- 3164US2014349309A1Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasisGILEAD BIOLOGICS INC·Filed 2014·Application pending·0 cites
- 3262US10209261B2Method for assessing protein identity and stabilityARMO BIOSCIENCES INC·Filed 2017·Granted Feb 19, 2019·0 cites·13 claims
- 3359US6197579B1Cell washing device and methodDENDREON CORP·Filed 1998·Granted Mar 6, 2001·42 cites·18 claims
- 3458US2012087917A1Lox and loxl2 inhibitors and uses thereofSMITH VICTORIA·Filed 2011·Application pending·0 cites
- 3554US2009196853A1Method of treating hepatitis virus infection with a multiphasic interferon delivery profileTHREE RIVERS PHARMACEUTICALS L·Filed 2009·Application pending·0 cites
- 3648US2021115116A1Methods for treating complement-mediated diseases and disordersBIOVERATIV USA INC·Filed 2018·Application pending·0 cites
- 3745US5789148ACell separation compositionDENDREON CORP·Filed 1995·Granted Aug 4, 1998·26 cites·8 claims
- 3845US2016068583A1Interleukin-10 Compositions and Uses ThereofARMO BIOSCIENCES INC·Filed 2014·Application pending·0 cites
- 3940US2005095224A1Compositions and method for treating hepatitis virus infectionFiled 2002·Application pending·0 cites
- 4037US2011076272A1Therapeutic methods and compositionsSMITH VICTORIA·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →